2018

07/26/2018 Revenue at 30 June 2018

Guerbet is reporting revenue of €389.6M for the first half of 2018, down 4.3% due to a highly unfavourable currency effect representing €26.1M. At constant exchange rates (CER), the Group’s revenue increased 2.1% to €415.7M.

[more]


07/10/2018 Guerbet and IBM Watson Health Announce Strategic Partnership for Artificial Intelligence in Medical Imaging, Liver

The agreement aims to develop and market software solutions to aid physicians’ in their treatment recommendations and follow-up care for liver cancer.

[more]


07/01/2018 Guerbet teams will attend ESHRE 2018!

ESHRE 2018 | Booth #477 | Barcelona International Convention Centre | July 1st to 4th |  Barcelona, Spain The 2018 edition of the ESHRE congress will be held In Barcelona, Spain from July 1st to 4th. The European Society of Human Reproduction and Embryology is the annual meeting to promote...

[more]


06/25/2018 Guerbet célèbre le 50ème anniversaire de son site de production pharmaceutique et de R&D à Aulnay-sous-Bois

Publication d’une étude sur l’impact économique du Groupe en France  Un historique local pour une ambition mondiale Un exemple de réussite industrielle française dans le domaine de la santé : 90 années d’innovations pour l’imagerie médicale Villepinte (France), le 25 juin 2018 (8h30...

[more]


04/26/2018 Guerbet announces the acquisition of a new microsphere technology to strengthen its interventional imaging range

• Acquisition of a technology developed by Occlugel, a French company specialized in the R&D of microspheres used in embolization; • This new technology will round out Guerbet’s Interventional Imaging solutions and create synergies with the Accurate range of anti-reflux...

[more]


04/18/2018 1st quarter 2018 revenue

1st quarter 2018 revenue €196.5 million at constant exchange rates: -3.2% Villepinte, April 18, 2018 - Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is reporting revenue of €183.2 million for the 1st quarter 2018, down 9.8% at current...

[more]


04/18/2018 GEAR 2023 strategic plan

Villepinte, April 18, 2018 – Guerbet (the “Company”), a global specialist in contrast agents and solutions for medical imaging, has released today its GEAR 2023 strategic plan. About Guerbet Guerbet is a leading global medical imaging player. The Company engages in the research, production...

[more]


Displaying results 1 to 7 out of 15
<< First < Previous 1-7 8-14 15-15 Next > Last >>